Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Bought by PDT Partners LLC

PDT Partners LLC grew its position in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 37.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 235,097 shares of the biopharmaceutical company's stock after purchasing an additional 63,804 shares during the quarter. PDT Partners LLC owned approximately 0.38% of Sage Therapeutics worth $1,277,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in SAGE. Geode Capital Management LLC increased its holdings in Sage Therapeutics by 0.3% in the third quarter. Geode Capital Management LLC now owns 1,242,854 shares of the biopharmaceutical company's stock valued at $8,975,000 after buying an additional 3,757 shares in the last quarter. SG Americas Securities LLC increased its stake in shares of Sage Therapeutics by 57.7% in the 4th quarter. SG Americas Securities LLC now owns 22,498 shares of the biopharmaceutical company's stock valued at $122,000 after purchasing an additional 8,228 shares in the last quarter. Inspire Investing LLC raised its holdings in Sage Therapeutics by 30.4% in the 4th quarter. Inspire Investing LLC now owns 75,313 shares of the biopharmaceutical company's stock worth $409,000 after purchasing an additional 17,541 shares during the period. Empowered Funds LLC purchased a new position in Sage Therapeutics during the fourth quarter worth approximately $91,000. Finally, Ieq Capital LLC acquired a new stake in Sage Therapeutics in the fourth quarter valued at approximately $57,000. 99.22% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

SAGE has been the subject of several research analyst reports. Scotiabank reduced their target price on Sage Therapeutics from $14.00 to $12.00 and set a "sector outperform" rating for the company in a research note on Wednesday, February 12th. Needham & Company LLC reiterated a "hold" rating on shares of Sage Therapeutics in a research report on Friday, April 25th. Wedbush reaffirmed a "neutral" rating and issued a $6.00 price target on shares of Sage Therapeutics in a research note on Wednesday, February 12th. HC Wainwright reiterated a "neutral" rating and set a $12.00 price objective (down from $14.00) on shares of Sage Therapeutics in a research note on Wednesday, February 12th. Finally, Canaccord Genuity Group decreased their target price on Sage Therapeutics from $9.00 to $8.00 and set a "hold" rating on the stock in a research report on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $8.81.

Sage Therapeutics Price Performance

Shares of SAGE stock traded down $0.16 on Tuesday, hitting $7.02. The stock had a trading volume of 347,147 shares, compared to its average volume of 1,215,799. The company's 50 day moving average price is $7.54 and its 200-day moving average price is $6.77. Sage Therapeutics, Inc. has a 1 year low of $4.62 and a 1 year high of $14.31. The firm has a market capitalization of $439.29 million, a P/E ratio of -1.06 and a beta of 0.20.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.02). The business had revenue of $14.06 million during the quarter, compared to analyst estimates of $14.12 million. Sage Therapeutics had a negative net margin of 971.50% and a negative return on equity of 68.18%. The company's revenue for the quarter was up 78.0% on a year-over-year basis. During the same quarter last year, the firm posted ($1.80) EPS. On average, equities analysts forecast that Sage Therapeutics, Inc. will post -3.52 EPS for the current year.

Sage Therapeutics Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.